RecruitingHeart FailurePolygenic Score
UPBEAT: Using Polygenic Scores to Guide BB Therapy in HF With Mildly Reduced EF
Eligible age
18–89 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study will use polygenic scores, a tool which describes differences in genetics, to examine effectiveness of beta blocker medication in heart failure patients with ejection fraction of 41-50 percent. The study will also assess beta blockers' effect on the changes in left ventricular end-systolic volume index by MRI.
Sponsor: David Lanfear
You may qualify if…
- ✓ Age 18-89 years
- ✓ Ejection Fraction (EF) \>40% and =\<50% by any modality within 1 year (must be most recent)
- ✓ Clinical diagnosis of HF within 1 year, evidenced by any one: Hospital discharge with primary or secondary HF diagnosis, ER discharge with primary diagnosis of HF, ambulatory diagnostic code for HF and diuretic use, BNP\>35 ng/L or NTproBNP \>125 ng/L at any time
- ✓ Expected ability to fully participate in study (can tolerate study processes, no long travel)
You may not qualify if…
- ✕ Unable to provide informed consent
- ✕ Previous documented EF =\< 35%
- ✕ Currently on BB =\>25% target dose
- ✕ Uncontrolled hypertension (systolic BP \> 180 at enrollment)
- ✕ Has contraindications to all BB or intolerance to metoprolol
- ✕ Systolic BP \< 100 or heart rate \<70
- ✕ Current cancer requiring active treatment
- ✕ Heart transplant or LVAD or expected in the next year
Where it's recruiting
Michigan
Detroit
Source: ClinicalTrials.gov · NCT07054489 · last updated 2026-05-07